series-c-plus
Stage
1
Investors
About
Lumicell develops a fluorescence-guided intraoperative imaging system and companion imaging agent (pegulicianine) to help surgeons detect residual cancer in real time, primarily for breast cancer surgery. Their LumiSystem comprises the LUMISIGHT imaging agent and the Lumicell DVS device, which the company reports has received FDA approval.
Explore Lumicell's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.